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Alzheimer’s disease (AD) is a fatal neurodegenerative disorder of brain. 
Nowadays there is only paliative treatment available, which can be further subdivided 
into two groups: acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate 
(NMDA) receptor antagonist. Donepezil, rivastigmine and galantamine represents 
AChEIs currently available for AD treatment. Tacrine is the first AChEIs to be 
approved for AD treatment, however, it was withdrawn from the market due to its side 
effects, especially due to its hepatotoxicity. 7-Methoxytacrine (7-MEOTA) is less toxic 
tacrine derivative preserving pharmacological profile of tacrine. 
This diploma thesis describes synthesis of multifunctional 7-MEOTA-
amantadine derivatives as potential drugs to confront AD. Using Ellmanʼs method, we 
have established their efficacy to inhibit acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE) in vitro. All new synthesized hybrids from 7-MEOTA-
amantadine family proved to be better inhibitors compared to both reference 
compounds 7-MEOTA and amantadine. Derivative 14 was even more potent in 
inhibiting AChE than tacrine. None of the new derivatives overwhelmed BChE 
inhibitory potency of tacrine. Inhibitory values of new 7-MEOTA-amantadine 
derivatives were ranging in micromolar to submicromolar IC50 values. Finally, 
molecular modeling studies on human AChE and BChE were performed in order to 
rationalize result from in vitro assays. According to in silico studies of chosen 
derivatives, 7-MEOTA-amantadine hybrids presumably bind to both anionic active 
sites of AChE. 
